Updated on 2022/10/30

写真a

 
USHIJIMA Yoko
 
Organization
Nagoya University Hospital Hematology Lecturer of hospital
Title
Lecturer of hospital

Degree 1

  1. 博士(医学) ( 2008.5   名古屋大学 ) 

Research Areas 1

  1. Life Science / Hematology and medical oncology

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    - 2008.5

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    - 2003.3

      More details

    Country: Japan

 

Papers 22

  1. Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells Reviewed International journal

    Kawashima Naomi, Ishikawa Yuichi, Kim Jeong Hui, Ushijima Yoko, Akashi Akimi, Yamaguchi Yohei, Hattori Hikaru, Nakashima Marie, Ikeno Seara, Kihara Rika, Nishiyama Takahiro, Morishita Takanobu, Watamoto Koichi, Ozawa Yukiyasu, Kitamura Kunio, Kiyoi Hitoshi

    NATURE COMMUNICATIONS   Vol. 13 ( 1 ) page: 1624   2022.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Nature Communications  

    Patient-derived xenografts (PDX) are widely used as human cancer models. Previous studies demonstrated clonal discordance between PDX and primary cells. However, in acute myeloid leukemia (AML)-PDX models, the significance of the clonal dynamics occurring in PDX remains unclear. By evaluating changes in the variant allele frequencies (VAF) of somatic mutations in serial samples of paired primary AML and their PDX bone marrow cells, we identify the skewing engraftment of relapsed or refractory (R/R) AML clones in 57% of PDX models generated from multiclonal AML cells at diagnosis, even if R/R clones are minor at <5% of VAF in patients. The event-free survival rate of patients whose AML cells successfully engraft in PDX models is consistently lower than that of patients with engraftment failure. We herein demonstrate that primary AML cells including potentially chemotherapy-resistant clones dominantly engraft in AML-PDX models and they enrich pre-existing treatment-resistant subclones.

    DOI: 10.1038/s41467-022-29304-6

    Web of Science

    Scopus

    PubMed

  2. Prophylactic antiviral therapy for hepatitis B virus surface antigen-positive patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy Reviewed

    Yamauchi Nobuhiko, Maruyama Dai, Choi Ilseung, Atsuta Yoshiko, Sakai Rika, Miyashita Kazuho, Moriuchi Yukiyoshi, Tsujimura Hideki, Kubota Nobuko, Yamamoto Go, Igarashi Tadahiko, Izutsu Koji, Yoshida Shinichiro, Kojima Kensuke, Uchida Toshiki, Inoue Yoshiko, Tsukamoto Norifumi, Ohtsuka Eiichi, Suzuki Sachiko, Inaguma Yoko, Ichikawa Satoshi, Gomyo Hiroshi, Ushijima Yoko, Nosaka Kisato, Kurata Mio, Tanaka Yasuhito, Ueda Ryuzo, Mizokami Masashi, Kusumoto Shigeru

    CANCER SCIENCE   Vol. 112 ( 5 ) page: 1943 - 1954   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Cancer Science  

    We conducted a nationwide retrospective analysis of 116 hepatitis B virus (HBV) surface antigen (HBsAg)-positive patients with diffuse large B-cell lymphoma (DLBCL) and 278 HBsAg-negative patients with DLBCL, as a control cohort, who received rituximab-containing regimens as an induction chemotherapy at 30 Japanese medical centers between January 2004 and December 2014. Hepatitis was defined as an absolute serum alanine aminotransferase (ALT) level of ≥100 U/L. HBV reactivation-related hepatitis was defined as hepatitis with an absolute serum HBV DNA level of ≥3.3 log IU/mL or an absolute increase of ≥2 log compared with the baseline value. HBsAg-positive patients were divided into three groups based on anti–HBV prophylactic therapy: no nucleos(t)ide analogue (non–NA, n = 9), lamivudine (LAM, n = 20), and entecavir (ETV, n = 87). The 4-year cumulative incidence (CI) of hepatitis in HBsAg-positive and HBsAg-negative patients was 21.1% and 14.6% (P =.081), respectively. The 4-year CI of HBV reactivation-related hepatitis was higher in HBsAg-positive patients than in HBsAg-negative patients (8.0% vs 0.4%; P <.001). Among HBsAg-positive patients, the 4-year CI of HBV reactivation-related hepatitis was the highest in the non–NA group (33.3%), followed by the LAM (15.0%) and ETV (3.8%) groups (P <.001). Of note, 3 non–NA patients (33%) and 1 LAM patient (5%) (but no ETV patients) died due to HBV hepatitis. Based on Cox multivariate analysis, HBsAg positivity was not associated with poor overall survival. Prophylactic use of ETV would reduce the occurrence of HBV reactivation-related hepatitis and mortality in HBsAg-positive DLBCL patients receiving rituximab-containing chemotherapy.

    DOI: 10.1111/cas.14846

    Web of Science

    Scopus

    PubMed

  3. Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation Reviewed

    Goto Tatsunori, Murata Makoto, Nishida Tetsuya, Terakura Seitaro, Kamoshita Sonoko, Ishikawa Yuichi, Ushijima Yoko, Adachi Yoshiya, Suzuki Satoshi, Kato Katsuyoshi, Hirakawa Akihiro, Nishiwaki Satoshi, Nishio Nobuhiro, Takahashi Yoshiyuki, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi

    STEM CELLS TRANSLATIONAL MEDICINE   Vol. 10 ( 4 ) page: 542 - 553   2021.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Stem Cells Translational Medicine  

    Mesenchymal stem cells (MSCs) have immunomodulatory properties and support hematopoiesis in the bone marrow (BM). To develop a new strategy to not only prevent graft-vs-host disease (GVHD) but also to enhance engraftment, a phase I trial of cord blood transplantation (CBT) combined with intra-BM injection of MSCs (MSC-CBT) was designed. Third-party BM-derived MSCs were injected intra-BM on the day of CBT. The conditioning regimen varied according to patient characteristics. GVHD prophylaxis was tacrolimus and methotrexate. The primary endpoint was toxicity related to intra-BM injection of MSCs. Clinical outcomes were compared with those of six controls who received CBT alone. Five adult patients received MSC-CBT, and no adverse events related to intra-BM injection of MSCs were observed. All patients achieved neutrophil, reticulocyte, and platelet recoveries, with median times to recoveries of 21, 35, and 38 days, respectively, comparable with controls. Grade II-IV acute GVHD developed in three controls but not in MSC-CBT patients. No patients developed chronic GVHD in both groups. At 1 year after transplantation, all MSC-CBT patients survived without relapse. This study shows the safety of MSC-CBT, and the findings also suggest that cotransplantation of MSCs may prevent GVHD with no inhibition of engraftment. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as number 000024291.

    DOI: 10.1002/sctm.20-0381

    Web of Science

    Scopus

    PubMed

  4. [A message to hematology residents in diverse career pathways]. Invited Reviewed

    Ushijima Y

    [Rinsho ketsueki] The Japanese journal of clinical hematology   Vol. 62 ( 7 ) page: 820 - 829   2021

     More details

    Authorship:Lead author   Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.11406/rinketsu.62.820

    PubMed

  5. Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features Reviewed

    Nishiwaki Satoshi, Kim Jeong Hui, Ito Masafumi, Maeda Matsuyoshi, Okuno Yusuke, Koyama Daisuke, Ozawa Yukiyasu, Gunji Masaharu, Osaki Masahide, Kitamura Kunio, Ushijima Yoko, Ishikawa Yuichi, Miyamura Koichi, Sugiura Isamu, Kiyoi Hitoshi

    FRONTIERS IN ONCOLOGY   Vol. 10   page: 586567   2020.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Frontiers in Oncology  

    Background: Recently, various blood cell lineages expressing the BCR-ABL fusion gene in Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) have been reported. However, the biological and clinical significance of these BCR-ABL lineages has not been established; therefore, we aimed to clarify the impacts of these different BCR-ABL-expressing lineages. Patients: Multi-lineage BCR-ABL expression (multi-Ph) was defined as BCR-ABL expression outside of the B-lineage compartment, as determined by fluorescence in situ hybridization (FISH) in peripheral blood neutrophils and bone marrow clots, and flow cytometry-sorted polymerase chain reaction (PCR). We analyzed IKZF1 deletion patterns by PCR, examined gene expression profiles using RNA sequencing, and compared treatment outcomes across different BCR-ABL-expressing lineages. Results: Among the 21 multi-Ph patients in our 59-patient cohort (36%), BCR-ABL expression was detected at the multipotential progenitor level. However, no IKZF1 deletion patterns or gene expression profiles were identified that were specific for multi-Ph. However, multi-Ph patients were found to have better survival rates than patients with uni-lineage BCR-ABL expression [event-free survival (EFS): 74 vs. 33%, P = 0.01; overall survival (OS): 79 vs. 44% at 4 years, P = 0.01]. In multivariate analyses, multi-Ph was identified as a good prognostic factor for both EFS and OS. Conclusion: We confirmed that more than one-third of Ph+ALL patients could be classified as mutli-Ph. Although no specific molecular characteristics were identified for multi-Ph, this phenotype was associated with better treatment outcomes.

    DOI: 10.3389/fonc.2020.586567

    Web of Science

    Scopus

    PubMed

  6. Identification of the novel deletion-type PML-RARA mutation associated with the retinoic acid resistance in acute promyelocytic leukemia Reviewed

    Hattori Hikaru, Ishikawa Yuichi, Kawashima Naomi, Akashi Akimi, Yamaguchi Yohei, Harada Yasuhiko, Hirano Daiki, Adachi Yoshiya, Miyao Kotaro, Ushijima Yoko, Terakura Seitaro, Nishida Tetsuya, Matsushita Tadashi, Kiyoi Hitoshi

    PLOS ONE   Vol. 13 ( 10 ) page: e0204850   2018.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1371/journal.pone.0204850

    Web of Science

    Scopus

    PubMed

  7. Mutation analysis of therapy-related myeloid neoplasms Reviewed

    Nishiyama Takahiro, Ishikawa Yuichi, Kawashima Naomi, Akashi Akimi, Adachi Yoshiya, Hattori Hikaru, Ushijima Yoko, Kiyoi Hitoshi

    CANCER GENETICS   Vol. 222   page: 38 - 45   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.cancergen.2018.02.006

    Web of Science

    Scopus

    PubMed

  8. Phase I study of cord blood transplantation with intrabone marrow injection of mesenchymal stem cells: A clinical study protocol Reviewed

    Goto Tatsunori, Murata Makoto, Terakura Seitaro, Nishida Tetsuya, Adachi Yoshiya, Ushijima Yoko, Shimada Kazuyuki, Ishikawa Yuichi, Hayakawa Fumihiko, Nishio Nobuhiro, Nishiwaki Satoshi, Hirakawa Akihiro, Kato Katsuyoshi, Takahashi Yoshiyuki, Kiyoi Hitoshi

    MEDICINE   Vol. 97 ( 17 ) page: e0449   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/MD.0000000000010449

    Web of Science

    Scopus

    PubMed

  9. Phase II study of intrabone single unit cord blood transplantation for hematological malignancies Reviewed

    Murata Makoto, Maeda Yoshinobu, Masuko Masayoshi, Onishi Yasushi, Endo Tomoyuki, Terakura Seitaro, Ishikawa Yuichi, Iriyama Chisako, Ushijima Yoko, Goto Tatsunori, Fujii Nobuharu, Tanimoto Mitsune, Kobayashi Hironori, Shibasaki Yasuhiko, Fukuhara Noriko, Inamoto Yoshihiro, Suzuki Ritsuro, Kodera Yoshihisa, Matsushita Tadashi, Kiyoi Hitoshi, Naoe Tomoki, Nishida Tetsuya

    CANCER SCIENCE   Vol. 108 ( 8 ) page: 1634 - 1639   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13291

    Web of Science

    Scopus

    PubMed

  10. Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies. Reviewed

    Tobinai K, Ogura M, Ishizawa K, Suzuki T, Munakata W, Uchida T, Aoki T, Morishita T, Ushijima Y, Takahara S

    International Journal of Hematology   Vol. 103 ( 1 ) page: 86 - 94   2016.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12185-015-1900-3

    Scopus

    PubMed

  11. The features of clearance in recombinant factor IX (BeneFIX® ). Reviewed

    Suzuki N, Takedani H, Hirakawa A, Ushijima Y, Matsushita T

    Haemophilia   Vol. 21 ( 5 ) page: 702 - 707   2015.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/hae.12672

    Web of Science

    Scopus

  12. Generation and Characterization of UL21-Null Herpes Simplex Virus Type 1. Reviewed

    Muto Y, Goshima F, Ushijima Y, Kimura H, Nishiyama Y

    Frontiers in Microbiology   Vol. 3 ( NOV ) page: 394   2012

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/fmicb.2012.00394

    Web of Science

    Scopus

    PubMed

  13. Bortezomib induces apoptosis in T lymphoma cells and natural killer lymphoma cells independent of Epstein-Barr virus infection. Reviewed

    Iwata S, Yano S, Ito Y, Ushijima Y, Gotoh K, Kawada JI, Fujiwara S, Sugimoto K, Isobe Y, Nishiyama Y, Kimura H

    International Journal of Cancer   Vol. 129 ( 9 ) page: 2263 - 2273   2011.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/ijc.25873

    Web of Science

    Scopus

    PubMed

  14. Herpes simplex virus UL56 interacts with and regulates the Nedd4-family ubiquitin ligase Itch. Reviewed

    Ushijima Y, Luo C, Kamakura M, Goshima F, Kimura H, Nishiyama Y

    Virology Journal   Vol. 7   page: 179   2010.8

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/1743-422X-7-179

    Web of Science

    Scopus

    PubMed

  15. Herpes simplex virus type 2 tegument protein UL56 relocalizes ubiquitin ligase Nedd4 and has a role in transport and/or release of virions. Reviewed

    Ushijima Y, Goshima F, Kimura H, Nishiyama Y

    Virology Journal     2009.10

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/1743-422X-6-168

  16. Herpes Simplex Virus Type 2 UL56 Interacts with the Ubiquitin Ligase Nedd4 and Increases its Ubiquitination. Reviewed

    Ushijima Y, Koshizuka T, Goshima F, Kimura H, Nishiyama Y

    Journal of Virology   Vol. 82 ( 11 ) page: 5220-5233   2008.6

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1128/JVI.02515-07

  17. Microarray analysis of transcriptional responses to infection by herpes simplex virus types 1 and 2 and their US3-deficient mutants. Reviewed

    Kamakura M, Nawa A, Ushijima Y, Goshima F, Kawaguchi Y, Kikkawa F, Nishiyama Y

    Microbes and Infection   Vol. 10 ( 4 ) page: 405-413   2008.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.micinf.2007.12.019

  18. Oligonucleotide Microarray Analysis of Gene Expression Profiles followed by a Real-time RT-PCR Assay in Chronic Active Epstein-Barr Virus Infection. Reviewed

    Ito Y, Shibata-Watanabe Y, Ushijima Y, Kawada J, Nishiyama Y, Kojima S, Kimura H

    Journal of Infectious Disease   Vol. 197   page: 663-666   2008.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1086/527330

  19. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Reviewed

    Nawa A, Luo C, Zhang L, Ushjima Y, Ishida D, Kamakura M, Fujimoto Y, Goshima F, Kikkawa F, Nishiyama Y

    Current Gene Therapy   Vol. 8 ( 3 ) page: 208-221   2008

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.2174/156652308784746422

  20. Intercellular trafficking and cytotoxicity of recombinant HSV-1 thymidine kinase fused with HSV-2 US11 RXP repeat peptide. Reviewed

    Luo C, Nawa A, Yamauchi Y, Kohno S, Ushijima Y, Goshima F, Kikkawa F, Nishiyama Y

    Virus Genes   Vol. 34 ( 3 ) page: 263-272   2007.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s11262-006-0013-8

  21. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Reviewed

    Ushijima Y, Luo C, Goshima F, Yamauchi Y, Kimura H, Nishiyama Y

    Microbes and Infection   Vol. 9 ( 2 ) page: 142-149   2007.2

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.micinf.2006.10.019

  22. Identification of nuclear export signal in UL37 protein of herpes simplex virus type 2. Reviewed

    Watanabe D, Ushijima Y, Goshima F, Takakuwa H, Tomita Y, Nishiyama Y

    Biochemical and biophysical research communications   Vol. 276 ( 3 ) page: 1248-1254   2000.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1006/bbrc.2000.3600

▼display all

Books 4

  1. 急性リンパ性白血病(ALL)の基礎と臨床

    牛島洋子, 清井仁( Role: Contributor ,  発症機序)

    医薬ジャーナル社  2017.1  ( ISBN:9784753228263

     More details

    Language:Japanese Book type:Textbook, survey, introduction

  2. 血液科研修ノート

    牛島洋子, 冨田章裕( Role: Contributor ,  バーキットリンパ腫)

    診断と治療社  2016.5  ( ISBN:9784787821775

     More details

    Language:Japanese Book type:Textbook, survey, introduction

  3. KEY WORD 感染症 第2版

    牛島洋子, 西山幸廣( Role: Contributor ,  欠損ウイルス)

    先端医学社  2008.8  ( ISBN:9784884074838

     More details

    Language:Japanese Book type:Textbook, survey, introduction

  4. 病原細菌・ウイルス図鑑

    牛島洋子, 西山幸廣( Role: Contributor ,  単純ヘルペスウイルス)

    北海道大学出版会  2017.11  ( ISBN:9784832982291

     More details

    Language:Japanese Book type:Textbook, survey, introduction

MISC 4

  1. 抗CD33抗体医薬 gemtuzumab ozogamicinの有用性

    牛島洋子, 清井仁

    医学のあゆみ   Vol. 265 ( 1 ) page: 31 - 35   2018.4

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  2. 分子標的療法

    牛島洋子, 清井仁

    日本臨床   Vol. 74   page: 14 - 19   2016.12

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  3. T細胞性リンパ系腫瘍に対する新規薬剤導入による新たな治療展開

    牛島洋子, 山本一仁

    血液内科   Vol. 62 ( 1 ) page: 51 - 57   2011.1

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

  4. 単純ヘルペスウイルスの増殖と病原性発現機構

    牛島洋子, 西山幸廣

    蛋白質核酸酵素   Vol. 54 ( 8 ) page: 953 - 960   2009.6

     More details

    Language:Japanese   Publishing type:Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media)  

Presentations 2

  1. Clonal Analysis of Acute Myeloid Leukemia secondary to Myeloproliferative Neoplasms International conference

    59th American Society of Hematology Annual Meeting and Exposition 

     More details

    Event date: 2017.12

    Language:English   Presentation type:Poster presentation  

    Country:United States  

  2. Clonal analysis of acute myeloid leukemia transformed from myeloproliferative neoplasms

    Yoko Ushijima, Yuichi Ishikawa, Hikaru Hattori, Naomi Kawashima, Shun Fujiwara, Seitaro Terakura, Masashi Sanada, Hitoshi Kiyoi

     More details

    Event date: 2017.10

    Language:English   Presentation type:Oral presentation (general)  

    Country:Japan  

KAKENHI (Grants-in-Aid for Scientific Research) 2

  1. 骨髄増殖性腫瘍とその二次性白血病におけるinitiating変異の同定と機能解析

    2019.4 - 2022.3

    科学研究費補助金  

      More details

    Authorship:Principal investigator 

  2. 単純ヘルペスウイルスUL56遺伝子のユビキチンシステム制御に関する研究

    2008 - 2009

    科学研究費補助金 

      More details

    Authorship:Principal investigator